

GLAXOSMITHKLINE PLC  
Form 6-K  
March 30, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending March 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Issued:  
Monday,  
30th  
March 2009,  
Philadelphia  
US & London  
UK

**Cervarix**  
**U.S.**  
**regulatory update**

**GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine**

GlaxoSmithKline today provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX®, its vaccine to prevent cervical cancer and cervical pre-cancer related to human papillomavirus types 16 and 18.

GSK has submitted final data from its Phase III

pivotal efficacy study, HPV-008, to the FDA. The FDA has previously reviewed interim data from the same trial. FDA review of this type of Biologics License Application (BLA) submission is expected to take six months, according to agency regulations.

"We are pleased to have reached this significant milestone for CERVARIX®. The data submitted to the FDA reaffirm our confidence in the vaccine's safety and efficacy profile," said Barbara Howe, M.D., Vice President and Director, North American Vaccine Development, GlaxoSmithKline. "We will continue working closely with the FDA in order to make this vaccine available to help protect the cervical health of girls and women in the

U.S.

"

HPV-008 is a Phase

III

clinical study of more than 18,600 women between 15-25 years of age, from 14 countries across Europe

, Asia-Paci

fic and Latin and

North America

The primary objective was to assess vaccine efficacy in the prevention of high-grade pre-cancerous cervical lesions (

CIN

2+) caused by human papillomavirus types 16 or 18

Secondary objectives included evaluation of vaccine efficacy in the prevention of pre-cancerous cervical lesions (

CIN

1+) and infections caused by virus types 16 or 18 or other cancer-causing virus types, as well as immune response and safety.

GSK will submit the data to a peer-reviewed journal in the coming months.

The BLA for the vaccine includes safety, efficacy and immune response data from clinical trials in nearly 30,000 females and reflects an ethnically diverse population.

To date, GSK's vaccine has been approved in more than 90 countries around the world including the 27 member countries of the European Union, Mexico, Australia, Singapore and the Philippines. Licensing applications have been submitted in more than 20 additional countries including Japan. GSK also submitted the vaccine to the World Health Organization (WHO) for prequalification in September 2007.

**S M Bicknell**

Company Secretary

30 March 2009

**Notes to Editors**

**Cervical Health Facts**

- Worldwide, every two minutes a woman dies of cervical cancer; each year more than 500,000 women will be newly diagnosed and more than 280,000 women will die

In the

U.S.

, after breast cancer, cervical cancer is the leading cause of cancer-related death in women between the ages of 20 to 39 in the

United States

Also, in the

U.S.

each year there are an estimated 3.5 million abnormal Pap smears, and more than 1.5 million precancerous lesions are diagnosed

**GlaxoSmithKline Biologicals -**

GSK's vaccines business is one of the world's leading vaccine companies and a leader in innovation. The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development. Headquartered in Belgium

, GSK Biologicals has 13 manufacturing sites strategically positioned around the globe. In 2008 GSK Biologicals distributed 1.1 billion doses of vaccines to 176 countries in both the developed and the developing world - an average of 3 million doses a day. Through its accomplished and dedicated workforce, GSK Biologicals applies its expertise to discover innovative vaccines that contribute to the health and well-being of people of all generations around the world.

**GlaxoSmithKline**

- one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit [www.gsk.com](http://www.gsk.com)

CERVARIX® is a registered trademark of the GlaxoSmithKline group of companies

**Enquiries:**

UK Media enquiries: Philip Thomson (020) 8047 5502  
David Outhwaite (020) 8047 5502  
Stephen Rea (020) 8047 5502

US Media enquiries: Nancy Pekarek (919) 483 2839  
Mary Anne Rhyne (919) 483 2839  
Kevin Colgan (919) 483 2839  
Sarah Alspach (919) 483 2839

European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564  
Sally Ferguson (020) 8047 5543  
Gary Davies (020) 8047 5503

US Analyst/ Investor enquiries: Tom Curry (215) 751 5419  
Jen Hill-Baxter (215) 751 7002

**Cautionary statement regarding forward-looking statements**

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2008

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: March 30, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc